Literature DB >> 18341720

Prostate specific antigen levels following transurethral resection of the prostate.

Roberto C Fonseca1, Cristiano M Gomes, Elton B Meireles, Geraldo C Freire, Miguel Srougi.   

Abstract

OBJECTIVE: Determine how serum prostate-specific antigen (t-PSA) levels and free PSA (f/t PSA) ratio change following transurethral resection of the prostate (TURP).
MATERIALS AND METHODS: Thirty men with a mean age of 67.0 +/- 4.2 years (range 46 to 84 years) underwent TURP for BPH between May 2005 and October 2005. Preoperative assessment included symptom evaluation with the International Prostate Symptom Score (I-PSS) and the prostate volume estimation by transrectal ultrasound. Total PSA and f/t PSA ratio were assessed before the procedure, as well as 30, 60 and 180 days after the TURP.
RESULTS: Clinical improvement after TURP, reflected by I-PSS score, was demonstrated as early as 30 days and remained stable until the end of the follow-up. Mean t-PSA declined 71% after TURP and 60 days after surgery the reduction reached its peak, stabilizing afterwards. It varied from 6.19 +/- 7.06 ng/mL before surgery to 1.75 +/- 1.66 ng/mL on day 60 (p < 0.001). The mean baseline f/t PSA ratio was 18.2% +/- 3.4% and was not significantly changed at any given time point in the postoperative period (p = 0.91). There were also no statistically significant differences in t-PSA or f/t PSA between patients with and without prostatitis at any time point (p = 0.23). Resected prostate fragments weighed 29.9 +/- 19.6 g, corresponding to 39.1% of the estimated preoperative prostate volume. Each gram of tissue resected decreased PSA by 0.15 +/- 0.11 ng/mL, while 1% prostate volume resected led to a reduction of 2.4% +/- 0.4% in serum PSA from baseline.
CONCLUSIONS: PSA decreases drastically in patients who undergo TURP. These low levels stabilize within 60 days after surgery. The f/t PSA ratio did not change, and the finding of chronic prostatitis did not affect the levels of these variables.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18341720     DOI: 10.1590/s1677-55382008000100007

Source DB:  PubMed          Journal:  Int Braz J Urol        ISSN: 1677-5538            Impact factor:   1.541


  4 in total

1.  Medications and surgical interventions for benign prostatic hyperplasia are potential confounders of prostate-specific antigen.

Authors:  Parth Modi; Brian T Helfand; Kevin T McVary
Journal:  Curr Urol Rep       Date:  2010-07       Impact factor: 3.092

2.  Changes in S-PSA after transurethral resection of prostate and its correlation to postoperative outcome.

Authors:  Mrinal Pahwa; Mayank Pahwa; Archna R Pahwa; Mohit Girotra; Arun Chawla; Ajay Sharma
Journal:  Int Urol Nephrol       Date:  2013-05-24       Impact factor: 2.370

3.  Impact of perioperative factors on nadir serum prostate-specific antigen levels after holmium laser enucleation of prostate.

Authors:  Mary Martos; Jonathan E Katz; Madhumita Parmar; Anika Jain; Nachiketh Soodana-Prakash; Sanoj Punnen; Mark L Gonzalgo; Feng Miao; Isildinha M Reis; Nicholas Smith; Hemendra N Shah
Journal:  BJUI Compass       Date:  2021-01-05

Review 4.  Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.

Authors:  Abhishek Bhat; Ruben Blachman-Braun; Thomas R W Herrmann; Hemendra N Shah
Journal:  World J Urol       Date:  2021-07-02       Impact factor: 3.661

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.